Ablation vs Surgery: Colon Cancer Liver Metastases

•Discuss the available loco-regional therapies proposed by Interventional Oncology •Evaluate the results of the current literature for ablation, TACE and radio-embolization
The France Foundation

Applying the Evidence on Antifibrotic Agents for IPF

These video-based roundtable discussions highlight key IPF updates provided at a recent annual meeting on pulmonary disease. Expert faculty reflect on new information on IPF and discuss the impact it has on patients.
The France Foundation

Cognitive Issues in Multiple Sclerosis

Cognitive Issues in Multiple Sclerosis summarizes information presented at the 5th Annual International Multiple Sclerosis Cognition Society (IMSCOGS) Meeting, which took place June 23-24, 2016 in New York City. The content includes information on neuropsychological assessment, cognition and the brain, cognitive interventions in MS, cognitive changes in pediatric MS, how cognition influences eve...
The France Foundation

Colorectal Cancer and Colorectal Liver Metastases — Epidemiology

•Identify the age and gender specific incidence of CRC •Describe the incidence of CRC based on tumor location •Evaluate the stage distribution of CRC at presentation
The France Foundation

Comorbidities and Selection of DMTs

Upon completion of this activity, participants should be better able to: •Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

Conventional and Stereotactic Radiotherapy for Lung Cancer

Upon completion of the activity, participants should be able to: •Distinguish the main types of radiation therapy (conventional and stereotactic) used for lung cancer •Discuss outcomes for Stage III lung cancer with various conventional treatment approaches •Explain recent experience with stereotactic ablative radiotherapy (SAbR), especially for treatment of patients with Stage I tumo...
The France Foundation

Diagnosis and Staging of CRC Liver Metastases

•Use imaging to diagnose and stage metastatic liver disease in patients with colorectal cancer
The France Foundation

Diagnosis, Staging and Treatment

•Describe key factors that inform cancer diagnosis and staging, including pathologic and imaging findings
The France Foundation

Early MS: Induction Therapy and Escalation Strategies

Upon completion of this activity, participants should be better able to: •Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

Elizabeth: Loves the outdoors but bothered by persistent cough and GERD

Upon completion of the activity, participants should be able to: • Examine emerging research related to IPF treatment • Select appropriate therapies that reflect current evidence and/or widely accepted guidelines that are individualized to patients • Recognize treatment success, disease progression and when/if to switch therapy
The France Foundation

Epidemiology

•Summarize key epidemiologic characteristics of hepatic cellular carcinoma
The France Foundation

Exploring the Patient Journey: Let’s Talk About ILD and IPF

Early referral and treatment is important! Join Dr. Amy Olson in this series of exciting, fast-paced videos on ILD and IPF.
The France Foundation

Exploring the Patient Journey: Let’s Talk About ILD and IPF

This discussion highlights the challenges with IPF diagnosis, explains when to refer, analyzes the need for personalized medicine, and demonstrates how to keep patients on treatment.
The France Foundation

Getting to Goal Can Be Difficult: Brian

Explore options for treating T2DM with new interactive, multimedia cases that provide specifics on the practical aspects of patient management of T2DM. Each case is an individualized experience in which patient outcomes depend on learner choices. Improve your skills while earning AMA PRA Category 1 Credit™.
The France Foundation

Getting to Goal Can Be Difficult: Louise

Explore options for treating T2DM with new interactive, multimedia cases that provide specifics on the practical aspects of patient management of T2DM. Each case is an individualized experience in which patient outcomes depend on learner choices. Improve your skills while earning AMA PRA Category 1 Credit™.
The France Foundation

Gwen: A lawyer with a history of MI has a dry cough and trouble with stairs

Upon completion of the activity, participants should be able to: • Examine emerging research related to IPF treatment • Select appropriate therapies that reflect current evidence and/or widely accepted guidelines that are individualized to patients • Recognize treatment success, disease progression and when/if to switch therapy
The France Foundation

Image-Guided Thermal Ablation of Lung Cancer

Upon completion of the activity, participants should be able to: •Explore recognized standards of care for thermal ablation of NSCLC as reflected in relevant treatment guidance, with special attention to imaging-related concerns and combination of IO and conventional treatment •Review clinical trial data describing efficacy and safety of ablative therapies
The France Foundation

Integrating IO into the Treatment Paradigm

•Discuss how guidelines relevant to IO practitioners are applied to actual clinical practice and the rationale for exceptions
The France Foundation

Is the delivery system a good match for your patients with COPD?

Drs. Gary T. Ferguson and Nicola A. Hanania address the following questions: •How often should the importance of optimizing inhaled delivery devices and patient preference/needs be reviewed? •What are the clues that an inhaled delivery system might not be working well for a specific patient? •What is known about gaps between patients and pulmonologists with regard to inhaler devices sys...
The France Foundation

Language of Oncology

•Review levels of evidence in oncologic literature •Review clinical trial design and how a trial design can determine the strength & level of evidence its results provide •Discuss methods of assessing response in oncology trials with a focus on the pros and cons of the different methods of response assessment •Discuss how endpoints are analyzed and presented in oncology trials
The France Foundation

Lung Cancer Pathology: From Atypical Adenomatous Hyperplasia to Adenocarcinoma

Upon completion of the activity, participants should be able to: •Explore lung adenocarcinoma classification, with a focus on the transition from pre-invasive to invasive adenocarcinoma •Examine how imaging and molecular testing inform histologic findings in lung adenocarcinoma classification and comprehension of the transition from pre-invasive to invasive disease •Describe data suppor...
The France Foundation

Lung Cancer Screening

LEARNING OBJECTIVES Upon completion of the activity, participants should be able to: •Review historical RCTs of lung cancer screening •Explore the purpose and utility of the ACR Lung-RADS™ •Identify individuals who may benefit from lung cancer screening
The France Foundation

Lung Cancer: Standard of Care Treatment Algorithms (Chemotherapy/Immunotherapy)

Upon completion of the activity, participants should be able to: •Review the current treatment algorithms for lung cancer •Identify appropriate roles for systemic therapy in various stages of lung cancer •Explain tumor-specific factors that influence selection of systemic treatment modalities
The France Foundation

Management of Breakthrough Disease Activity in MS

Upon completion of this activity, participants should be better able to: •Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

Management of Unresectable Colorectal Carcinoma - Liver Metastases

•Describe standard chemotherapy regimens for unresectable colorectal carcinoma liver metastases (CLM) •Discuss clinical outcomes of systemic treatment for unresectable CLM •Define the role of Interventional Radiology (IR) locoregional therapies (LRTs) in treatment of unresectable CLM •Explain efficacy and safety outcomes of IR LRTs for unresectable CLM
The France Foundation

Staging and Diagnosis of Lung Cancer

Upon completion of the activity, participants should be able to: •Discuss the role of imaging in lung cancer diagnosis and staging •Review descriptors identified in the 8th Edition of TNM Staging for Lung Cancer •Review methods for tissue acquisition for lung cancer diagnosis and mediastinal staging
The France Foundation

Standard of Care Treatment - Surgery

•Discuss the current surgical techniques and possibilities of liver surgery •Describe the limits of surgery, complications, and recurrence rate
The France Foundation

Standard of Care Treatment Guidelines and Algorithms

•Explore recognized standards of care •Discuss the role of IO, other treatments, and combinations in guideline algorithms
The France Foundation

Stepping up or stepping down – which direction for COPD patients?

Drs. Gary T. Ferguson and James F. Donohue address the following questions: •What are new findings related to LAMA/LABA fixed dose combinations? •What are the considerations and issues with stepping up to triple therapy? •When is it safe and appropriate to step down from triple therapy to a LAMA/LABA fixed dose combination?
The France Foundation

Systemic Therapy in Liver-Limited CRC

•Identify the age and gender specific incidence of CRC •Describe the incidence of CRC based on tumor location •Evaluate the stage distribution of CRC at presentation
The France Foundation

Targeting B-cells in Primary Progressive MS (PPMS)

Upon completion of this activity, participants should be better able to: •Analyze data from clinical trials of disease modifying therapies to inform personalized treatment and monitoring of outcomes for patients with MS •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

The Case for Integration of Locoregional Therapy with Systemic Therapy in Patients with Metastatic Colorectal Cancer (mCRC)

•Evaluate when IO techniques can be proposed in the treatment algorithm •Discuss conceptual arguments to integrate locoregional therapy (radio-embolization) into our current treatment algorithm
The France Foundation

The Gut Microbiota in MS

Upon completion of this activity, participants should be better able to: •Integrate new and emerging information on the pathophysiology of MS, including modifiable risk factors, in the development of individualized treatment plans •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

The Role of Surgery for Non-Small Cell Lung Cancer

Upon completion of the activity, participants should be able to: •Explore different surgical approaches to NSCLC •Determine the extent of resection required based on the patient’s surgical risk and tumor factors •Review data from clinical trials examining the role of different surgical strategies of patients with NSCLC
The France Foundation

Toni: Too tired to continue teaching and experiencing painful heartburn

Upon completion of the activity, participants should be able to: • Examine emerging research related to IPF treatment • Select appropriate therapies that reflect current evidence and/or widely accepted guidelines that are individualized to patients • Recognize treatment success, disease progression and when/if to switch therapy
The France Foundation

Treatment Options : Ablation

•Describe the key principles and clinical rationale for Ablation
The France Foundation

Treatment Options: Embolotherapy for HCC

•Describe the key principles and clinical rationale for Embolotherapy
The France Foundation

Treatment Options: Liver Transplantation

•Describe the key principles and clinical rationale for Transplantation
The France Foundation

Treatment Options: Resection

Describe the key principles and clinical rationale for Resection
The France Foundation

Treatment Options: Systemic Treatment

Describe the key principles and clinical rationale for Systemic Treatments
The France Foundation

Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS

Upon completion of this activity, participants should be better able to: •Integrate new and emerging information on the pathophysiology of MS, including modifiable risk factors, in the development of individualized treatment plans •Access reliable and evidence-based resources in order to stay current with advances in the management of MS
The France Foundation

What Do the Experts Say about New Developments in the Diagnosis of ILD?

These video-based roundtable discussions highlight key IPF updates provided at a recent annual meeting on pulmonary disease. Expert faculty reflect on new information on IPF and discuss the impact it has on patients.
The France Foundation

What’s Next for IPF Therapy?

These video-based roundtable discussions highlight key IPF updates provided at a recent annual meeting on pulmonary disease. Expert faculty reflect on new information on IPF and discuss the impact it has on patients.
The France Foundation

What’s the 2017 GOLD standard for managing patients with COPD?

Drs. James Donohue and Gary Ferguson discuss changes regarding the management of COPD and new recommendations regarding the use of ICS.
The France Foundation

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.